The 45-year story of the development of an anti-aldosterone more specific than spironolactone

@article{Mnard2004The4S,
  title={The 45-year story of the development of an anti-aldosterone more specific than spironolactone},
  author={J. M{\'e}nard},
  journal={Molecular and Cellular Endocrinology},
  year={2004},
  volume={217},
  pages={45-52}
}
  • J. Ménard
  • Published 2004
  • Medicine
  • Molecular and Cellular Endocrinology
At the early stage of its development in 1957, the daily dose of spironolactone necessary to improve various pathological conditions was not precisely determined and dose-dependent sexual side effects limited its long-term use. Prescription of high daily doses and absence of selectivity for the mineralocorticoid receptor explain these limitations. The 9-11alpha epoxy group added to mexrenone by the Ciba-Geigy chemists in 1984 and improved chemical synthesis at Searle, permitted the original… Expand
Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.
  • D. Sica
  • Medicine
  • Methodist DeBakey cardiovascular journal
  • 2015
Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis
  • D. Sica
  • Medicine
  • Heart Failure Reviews
  • 2005
The pharmacological treatment of primary aldosteronism
The risks and benefits of aldosterone antagonists
  • D. Sica
  • Medicine
  • Current heart failure reports
  • 2005
Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
Efficacy and tolerance of spironolactone in essential hypertension.
Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro.
Evaluation of aldosterone antagonists in healthy man.
...
1
2
3
4
5
...